• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

马体内β-淀粉样蛋白(40和42)及磷酸化tau蛋白181血药浓度的初步研究

A Pilot Study on Blood Concentration of β-Amyloid (40 and 42) and Phospho-Tau 181 in Horses.

作者信息

Gazzano Valentina, Curadi Maria Claudia, Capsoni Simona, Baragli Paolo, Kêdzierski Witold, Cecchi Francesca, Gazzano Angelo

机构信息

Department of Veterinary Sciences, University of Pisa, 56126 Pisa, Italy.

Department Neuroscience & Rehabilitation, University of Ferrara, 44124 Ferrara, Italy.

出版信息

Vet Sci. 2025 Jun 23;12(7):610. doi: 10.3390/vetsci12070610.

DOI:10.3390/vetsci12070610
PMID:40711270
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12300970/
Abstract

In humans, aging is often accompanied by cognitive decline, as seen in Alzheimer's disease. In contrast, the aging process in horses remains poorly characterized. This study aims to explore the presence of blood-based biomarkers associated with cognitive degeneration in this species. Twenty-three Arabian horses were enrolled, and 5 mL of blood was collected from each to measure serum levels of β-amyloid peptides (Aβ40 and Aβ42) and phosphorylated tau protein (pTau181), both considered reliable indicators of cognitive impairment in other species. Aβ42 was undetectable in all samples, while pTau181 ranged from 5.38 to 54.42 pg/mL and Aβ40 from 67.4 to 743.9 pg/mL. Statistical analysis of the data, performed with the non-parametric Spearman test, did not reveal any correlation between age and the concentrations of Aβ40 and pTau. The pTau/Aβ40 ratio also did not appear to be correlated with the age of the subjects. Interestingly, none of the horses exhibited behavioral changes or clinical signs suggestive of cognitive dysfunction. This absence of symptoms may be related to the undetectable levels of Aβ42, the isoform considered crucial in initiating tau phosphorylation and subsequent neurodegeneration, despite possibly being present at concentrations higher than those typically found in healthy humans.

摘要

在人类中,衰老往往伴随着认知能力下降,如在阿尔茨海默病中所见。相比之下,马的衰老过程仍未得到充分描述。本研究旨在探索该物种中与认知退化相关的血液生物标志物的存在情况。招募了23匹阿拉伯马,每匹马采集5毫升血液,以测量血清中β-淀粉样肽(Aβ40和Aβ42)和磷酸化tau蛋白(pTau181)的水平,这两者在其他物种中均被视为认知障碍的可靠指标。所有样本中均未检测到Aβ42,而pTau181的范围为5.38至54.42 pg/mL,Aβ40的范围为67.4至743.9 pg/mL。使用非参数Spearman检验对数据进行统计分析,未发现年龄与Aβ40和pTau浓度之间存在任何相关性。pTau/Aβ40比值似乎也与受试者的年龄无关。有趣的是,没有一匹马表现出行为变化或提示认知功能障碍的临床症状。这种无症状可能与Aβ42水平未被检测到有关,Aβ42这种异构体被认为在引发tau磷酸化和随后的神经退行性变中至关重要,尽管其浓度可能高于健康人类中的典型浓度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1491/12300970/941ba13cd8fd/vetsci-12-00610-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1491/12300970/941ba13cd8fd/vetsci-12-00610-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1491/12300970/941ba13cd8fd/vetsci-12-00610-g001.jpg

相似文献

1
A Pilot Study on Blood Concentration of β-Amyloid (40 and 42) and Phospho-Tau 181 in Horses.马体内β-淀粉样蛋白(40和42)及磷酸化tau蛋白181血药浓度的初步研究
Vet Sci. 2025 Jun 23;12(7):610. doi: 10.3390/vetsci12070610.
2
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
3
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity.肾功能对阿尔茨海默病血液生物标志物的影响:对预测淀粉样蛋白-β阳性的意义。
Alzheimers Res Ther. 2025 Feb 19;17(1):48. doi: 10.1186/s13195-025-01692-z.
4
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
5
The ratio of plasma pTau217 to Aβ42 outperforms individual measurements in detecting brain amyloidosis.在检测脑淀粉样变性方面,血浆pTau217与Aβ42的比值比单独测量更具优势。
medRxiv. 2025 Jan 10:2024.12.07.24318640. doi: 10.1101/2024.12.07.24318640.
6
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.脑脊液和血液生物标志物在阿尔茨海默病诊断中的应用:系统评价和荟萃分析。
Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8.
7
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Sexual Harassment and Prevention Training性骚扰与预防培训
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.

本文引用的文献

1
The role of intracellular and extracellular copper compartmentalization in Alzheimer's disease pathology and its implications for diagnosis and therapy.细胞内和细胞外铜分隔在阿尔茨海默病病理学中的作用及其对诊断和治疗的意义。
Front Neurosci. 2025 Mar 12;19:1553064. doi: 10.3389/fnins.2025.1553064. eCollection 2025.
2
Defining benefit: Clinically and biologically meaningful outcomes in the next-generation Alzheimer's disease clinical care pathway.定义获益:下一代阿尔茨海默病临床护理路径中具有临床和生物学意义的结果。
Alzheimers Dement. 2025 Feb;21(2):e14425. doi: 10.1002/alz.14425. Epub 2024 Dec 19.
3
Global burden of Alzheimer's disease and other dementias attributed to metabolic risks from 1990 to 2021: results from the global burden of disease study 2021.
1990年至2021年归因于代谢风险的阿尔茨海默病和其他痴呆症的全球负担:全球疾病负担研究2021的结果
BMC Psychiatry. 2024 Dec 18;24(1):910. doi: 10.1186/s12888-024-06375-x.
4
The Memory Abilities of the Elderly Horse.老马的记忆能力
Animals (Basel). 2024 Oct 25;14(21):3073. doi: 10.3390/ani14213073.
5
Biomarker-based staging of Alzheimer disease: rationale and clinical applications.基于生物标志物的阿尔茨海默病分期:原理与临床应用。
Nat Rev Neurol. 2024 Apr;20(4):232-244. doi: 10.1038/s41582-024-00942-2. Epub 2024 Mar 1.
6
Tau and Alzheimer's disease: Past, present and future.tau 与阿尔茨海默病:过去、现在与未来。
Cytoskeleton (Hoboken). 2024 Jan;81(1):116-121. doi: 10.1002/cm.21822. Epub 2023 Dec 21.
7
Advances in single molecule arrays (SIMOA) for ultra-sensitive detection of biomolecules.单分子阵列 (SIMOA) 在生物分子超灵敏检测方面的进展。
Talanta. 2024 Apr 1;270:125529. doi: 10.1016/j.talanta.2023.125529. Epub 2023 Dec 10.
8
Amyloid futures in the expanding pathology of brain aging and dementia.脑老化和痴呆症不断扩展的病理学中的淀粉样蛋白未来。
Alzheimers Dement. 2023 Jun;19(6):2605-2617. doi: 10.1002/alz.12896. Epub 2022 Dec 19.
9
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.阿尔茨海默病中的血磷酸化tau:分析、解释和临床应用。
Nat Rev Neurol. 2022 Jul;18(7):400-418. doi: 10.1038/s41582-022-00665-2. Epub 2022 May 18.
10
Tauopathies: new perspectives and challenges.tau 病:新视角与新挑战。
Mol Neurodegener. 2022 Apr 7;17(1):28. doi: 10.1186/s13024-022-00533-z.